Our technology base is microporous polysaccharide Microspheres. These are derived from purified plant starch that is transformed through a unique chemical process developed in-house, which allows the control of microsphere size from 10 μm to 2000 μm. The microspheres are naturally bio- absorbable and biodegradable.
We have developed thirteen microsphere families with varying characteristics for wide use across our strategic markets. In-house research and development teams have adapted the technology to create gels, absorbable sponges, unwoven absorbable fibers, naturally degradable films and microporous polysaccharide microspheres.
We have a dedicated and highly experienced research and development team that is supported through the integration of the services we offer as a company. Our development is expedited due to our ability to develop in parallel with analytic, formulation and manufacturing expertise.
In 2019 the company received CE approval for a technology product that is formulated for use in vascular occlusion in the treatment of tumors in liver and lung alongside cytostatic drugs. The product is manufactured at Magle Chemoswed and marketed by a distribution partner under the trade-name of EmboCept S. Alongside this we continue to increase our portfolio in the vascular occlusion area. We are actively working on our portfolio growth and building an occlusion franchise, through expansion in the product range. Alongside this we are supporting our distribution partner to enter the North American, Chinese and expanding European reach with the EmboCept range of products.
Our first advanced wound care product is currently in registration. A formulated hydrogel containing an antimicrobial for the treatment of chronic and diabetic wounds. The product is expected to receive CE approval in 2020 and be distributed as a wound care hydrogel in Europe, Middle East and Russia through our existing agreement with our Russian and German partner.
Based on our technology we have successfully patented a first in class product for the detection of pancreatic fluid leakage during surgical procedures. The product has been developed based on our technology and in partnership with the University Hospital of Heidelberg.
EmboCept S® is a microsphere based medical device used in vascular occlusion of liver and lung tumours and is marketed by PharmaCept
SmartGel is a non-allergenic hydrogel based on our unique microsphere technology. It contains PHMB incorporated into fully biodegradable starch microspheres, which are suspended in a gel matrix for optimal infection prevention and treatment. The gel delivers moisture to the wound, whilst maintaining enough absorption capacity for exudate, debris and bacteria and is currently marketed by AXXO
SmartPan is a first in class product for the detection of pancreatic fluid leakage during surgical procedures. SmartPan is currently under review by a European Notified Body for registration in Europe.
We have a rich pipeline of future projects based on our technology, some of our current projects include.
EmboCept M® for the treatment of benign prostatic hyperplasia.
EmboCept L® for the treatment of uterine fibroids.
SmartGel II an advanced wound care hydrogel highly effective in the removal and prevention of wound biofilm.
SmartBone is an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures.
Contact us to become a distributor for our products.